Fremanezumab  (Synonyms: 瑞玛奈珠单抗; TEV-48125; LBR-101; PF-04427429; RN-307)

Fremanezumab (TEV-48125) is a humanized lgG2a monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC₅₀ values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC₅₀ value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine^[1][2][3].

CALCA/CGRP

Fremanez Raimab (10 μM，6 小时) 对抗小鼠 CGRP 对 C57Bl 小鼠小胶质细胞原代培养中 LPS (HY-D1056) 诱导的 IL1β、IL6 和 IL12 转录本增加的浓度依赖性抑制作用，但单独在 LPS 孵育时不改变小胶质细胞的激活^[1]。
Fremanezumab (72 小时) 阻止小鼠 CGRP 对第 30 天 MOG_35-55 免疫的 NOD 衍生脾细胞增殖的浓度依赖性抑制，但单独不改变淋巴细胞增殖^[1]。
Fremanezumab (1-100 ng，1 小时) 降低对人和小鼠 CGRP 的免疫检测，IC₅₀ 值分别为 7.94 nM 和 19.6 nM^[1]。
Fremanezumab (0.00001-1 μM) 显著抑制人 αCGRP、鼠 αCGRP 以及代谢稳定的 CGRP 类似物 SAX 在大鼠大脑基底动脉段中诱导的血管舒张效应，并降低 CGRP (pEC₅₀ 从 8.0 降至 6.3) 和 SAX (pEC₅₀ 从 7.2 降至 6.3) 的效力^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Fremanezumab (100 mg/kg, 皮下注射, 每 2 周一次) 在 NOD 小鼠中对疾病进展、存活率、脊髓神经退行性变或先天/适应性免疫反应无影响^[1]。
Fremanezumab (30 mg/kg，静脉注射，一次) 在麻醉雄性大鼠中选择性地抑制皮质扩散抑制 (CSD) 引起的 Aδ 脑膜痛觉感受器的激活^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

145.5 kDa

1655501-53-3

液体

Colorless to light yellow

瑞玛奈珠单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG2 kappa

• [1]. Pistolesi A, et al. The anti-CGRP mAb Fremanezumab reverts the anti-inflammatory effects of CGRP in vitro but does not alter disease evolution in a mouse model of progressive multiple sclerosis. Eur J Pharmacol. 2025 May 15;995:177415.  [Content Brief]

  [2]. Grell AS, et al. Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction. Eur J Pharmacol. 2019 Dec 1;864:172726.  [Content Brief]

  [3]. Melo-Carrillo A, et al. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors. J Neurosci. 2017 Nov 1;37(44):10587-10596.  [Content Brief]